Source: International Congress 2018 – Innovative therapies in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Riccio (Genoa, Italy), P. Mauri (Segrate, Italy), M. Bartezaghi (Origgio, Italy), F. Saccheri (Origgio, Italy), G. Canonica (Milan, Italy). Serum GAL3 predict response in omalizumab-treated patients with severe allergic asthma: the PROXIMA study. 604

Member's Comments

No comment yet.

Related content which might interest you: Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study Source: International Congress 2017 – Asthma management Year: 2017 Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study Source: ERJ Open Res, 4 (3) 00022-2018; 10.1183/23120541.00022-2018 Year: 2018 Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Omalizumab significantly improves FEV1 in patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Late Breaking Abstract - The blood eosinophils count as a predictor of the response for omalizumab (OMA) in patients suffering from severe allergic asthma Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care Year: 2007 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Efficacy of Omalizumab in adult and pediatric severe allergic asthma according to presence of multiple allergic comorbidities: evidence from the STELLAIR study. Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 Omalizumab improves lung function in severe persistent allergic (IgE-mediated) asthma patients: Pooled data from 5 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Associations of serum cytokine levels with asthma, wheeze and allergic rhinitis symptoms in 5-years old children: a population-based study Source: Virtual Congress 2020 – Novel mechanisms and management of paediatric asthma Year: 2020 Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 IL-33 in patients with severe uncontrolled allergic asthma Source: International Congress 2017 – "Alarming" immunological patterns in asthma Year: 2017 Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study Source: Eur Respir J, 51 (5) 1702523; 10.1183/13993003.02523-2017 Year: 2018 Prediction of the risk of future exacerbations in patients with severe persistent allergic asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005